Research suggests ARA-290 is a synthetic peptide designed from structural features of erythropoietin and investigated for receptor-selective signaling. This article focuses on the peptide’s design rationale and experimental receptor studies. It does not describe treatment, clinical use, or consumer benefits.
A peptide designed from a larger protein
ARA-290, also called pHBSP in research literature, is an engineered short peptide modeled on a surface region of erythropoietin. The design question was whether a smaller sequence could be used to investigate signaling associated with a receptor complex distinct from the canonical erythropoietin receptor. The design rationale is a starting point for research, not proof that every proposed interaction occurs in every model.
A 2014 study in mouse mesenchymal-derived cells examined signaling through an erythropoietin-receptor/CD131 complex. The authors reported that ARA-290 interacted with that proposed heteroreceptor and distinguished it from the canonical receptor in their experiments. These findings are tied to the methods and cell models used in that paper (primary study in PubMed).
Why receptor selectivity is studied
Receptor selectivity research compares how a molecule interacts with different receptor configurations. Investigators may combine cell models, receptor-specific perturbations, molecular assays, and controls to test whether an observed response depends on a particular receptor component. A claim of selectivity should remain bounded by the systems and measurements tested.
The phrase “erythropoietin-derived” describes the design relationship; it does not mean ARA-290 is equivalent to erythropoietin. Likewise, a finding about one receptor complex does not establish all downstream effects or a clinical outcome.
How to interpret the experimental literature
A 2015 paper described ARA-290 as an 11-amino-acid peptide modeled from the three-dimensional structure of erythropoietin’s helix-B surface and discussed the innate-repair-receptor hypothesis. That paper offers a mechanistic framework, while each experimental result still needs to be evaluated by its model, endpoint, and controls (mechanistic research paper).
A careful review distinguishes receptor binding or pathway measurements from organism-level outcomes. It also notes when the paper uses engineered cells, cultured cells, animals, or human participants. Those models answer different questions and should not be collapsed into a single broad claim.
For related site information, see the ARA-290 research-material listing, our existing ARA-290 signaling article, and the peptide-receptor communication overview. These pages provide catalog and research context; none implies a treatment use.
Questions for evaluating ARA-290 studies
- Which receptor configuration and cell type were studied?
- What evidence supports the proposed receptor interaction?
- Were receptor components blocked, altered, or compared with controls?
- Which outcomes were directly measured, and which were proposed interpretations?
- Does the paper clearly separate model-specific findings from broader hypotheses?
Evidence boundaries
The cited studies support discussion of peptide design and experimental receptor research. They do not establish a treatment claim, personal-use safety, or an outcome for a person or animal. Any conclusion should remain tied to the tested model and reported endpoint.
Frequently asked questions
What does “erythropoietin-derived” mean here? It refers to the structural design inspiration for the peptide; it does not make ARA-290 the same molecule as erythropoietin.
Does a receptor study establish a clinical effect? No. Receptor and cell-model findings are mechanistic evidence, not proof of a clinical outcome.
Why compare receptor complexes? Comparing them helps researchers test which receptor components are involved in a measured response.
For lawful laboratory, analytical, and in-vitro research discussion only. For Research Use Only. Not for human consumption, medical, or veterinary use.

TB-500 Research Material — 5mg